Chemotherapy with Immunotherapy for Biliary Cancer

Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study

Recruiting Observational Study
Unresectable Biliary Tract Cancer Dynamic Prediction Model Immunotherapy
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
332 (estimated)
Sponsor
Zhongda Hospital · Other
Who this trial is looking for

This trial is looking for adults with advanced biliary cancer who are unable to have surgery. Taking part involves being evaluated for your health and tumor characteristics before starting a combination treatment of chemotherapy and immunotherapy.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with biliary malignancy.
  • I am at least 18 years old.
  • I have liver function classified as Child-Pugh A or B.
  • I have an expected survival time of 3 months or more.
  • My ECOG performance status score is 2 or less.
  • I meet specific laboratory test parameters.

You may not be able to join if

  • I have other types of malignant tumors.
  • I have moderate to severe ascites.
  • I have had any local treatments or surgery within the last 4 weeks.
  • I have severe liver dysfunction.
  • I have severe comorbidities like refractory hypertension or CPT grade 2 arrhythmia.
  • I am infected with HIV.
  • I am pregnant or breastfeeding.
  • I have acute or chronic mental disorders.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This study focused on the longitudinal tumor burden profile (tumor macro features, histopathological types and imaging features, etc.), liver function, health status, tumor biomarkers, and serological indicators of patients with unresectable biliary malignancies before chemotherapy combined with immunotherapy to build a dynamic prediction model. Based on this model, risk stratification of BTC pati…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 1\. Confirmed by histopathological diagnosis and/or clinical diagnosis (typical imaging features, clinical manifestations, laboratory examination, etc.) as biliary malignancy (Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Biliary maligna…
Contacts

Gao-Jun Teng, M.D

+86-02583272121

gjteng@vip.sina.com

CONTACT